La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ShanXi C&Y Pharmaceutical GroupLTD Gestione

Gestione criteri di controllo 4/4

ShanXi C&Y Pharmaceutical GroupLTD's Il CEO è Qun Zhao, nominato in Oct2021, ha un mandato di 2.83 anni. possiede direttamente 5.39% delle azioni della società, per un valore di CN¥ 113.25M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7 anni e 4.5 anni.

Informazioni chiave

Qun Zhao

Amministratore delegato

CN¥943.8k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	2.9yrs
Proprietà del CEO	5.4%
Durata media del management	7.1yrs
Durata media del Consiglio di amministrazione	4.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

May 27

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Mar 06

AMMINISTRATORE DELEGATO

Qun Zhao (53 yo)

2.9yrs

Mandato

CN¥943,800

Compensazione

Mr. Qun Zhao has been President of ShanXi C&Y Pharmaceutical Group Co., Ltd. since October 26, 2021 and its a Director since June 1, 2010. Mr. Zhao served as Chairman of the Board at ShanXi C&Y Pharmaceuti...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Qun Zhao	President & Director	2.9yrs	CN¥943.80k	5.39% CN¥ 112.3m
Yanjie He	Financial Director	6yrs	CN¥558.90k	Nessun dato
Junxian Yu	Secretary	8.2yrs	CN¥774.80k	0.42% CN¥ 8.7m
Ying Min Yu	Chief Engineer	8.2yrs	CN¥453.90k	0.030% CN¥ 629.9k

7.1yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 300254 è esperto e expertise (durata media dell'incarico 7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Qun Zhao	President & Director	14.3yrs	CN¥943.80k	5.39% CN¥ 112.3m
Junxian Yu	Secretary	12.7yrs	CN¥774.80k	0.42% CN¥ 8.7m
Hairong Zhong	Vice Chairman	9.5yrs	CN¥668.30k	0.91% CN¥ 18.9m
Lequn Huang	Chairman	4.6yrs	CN¥89.40k	2.08% CN¥ 43.3m
Hao Gao	Independent Director	4.6yrs	CN¥60.00k	Nessun dato
Tao Ju	Independent Director	4.6yrs	CN¥60.00k	Nessun dato
Xuhong Zhang	Supervisor	14.3yrs	Nessun dato	Nessun dato
Guowen Wei	Supervisor	11.3yrs	Nessun dato	Nessun dato
Haibo Zhu	Supervisory Board Chairman	1.6yrs	Nessun dato	0.048% CN¥ 1.0m
Zhukun Lou	Independent Director	2yrs	CN¥60.00k	Nessun dato
Guowei Fang	Independent Director	1.3yrs	CN¥30.00k	Nessun dato

4.6yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300254 sono considerati esperti (durata media dell'incarico 4.5 anni).

ShanXi C&Y Pharmaceutical GroupLTD Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ShanXi C&Y Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 09, 2024

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.063 (vs CN¥0.091 loss in 2Q 2023)

Investor sentiment improves as stock rises 19%

New minor risk - Shareholder dilution

ShanXi C&Y Pharmaceutical Group Co.,LTD. to Report First Half, 2024 Results on Aug 29, 2024

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

Investor sentiment improves as stock rises 29%

Investor sentiment deteriorates as stock falls 23%

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 13, 2024

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

ShanXi C&Y Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 09, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.50 loss in FY 2022)

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

New minor risk - Share price stability

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Third quarter 2023 earnings released: EPS: CN¥0.043 (vs CN¥0.011 loss in 3Q 2022)

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.089 loss in 2Q 2022)

New minor risk - Share price stability

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: CN¥0.009 loss per share (vs CN¥0.007 loss in 1Q 2022)

Insufficient new directors

Now 22% undervalued

Third quarter 2022 earnings released: CN¥0.011 loss per share (vs CN¥0.006 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.089 loss per share (vs CN¥0.022 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.007 loss per share (vs CN¥0.005 profit in 1Q 2021)

ShanXi C&Y Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2021 Results on Apr 29, 2022

Now 23% undervalued

Now 24% undervalued

Second quarter 2021 earnings released: CN¥0.022 loss per share (vs CN¥0.15 loss in 2Q 2020)

ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing.

First quarter 2021 earnings released: EPS CN¥0.005 (vs CN¥0.21 loss in 1Q 2020)

Full year 2020 earnings released: CN¥1.21 loss per share (vs CN¥0.025 profit in FY 2019)

New 90-day low: CN¥5.57

New 90-day low: CN¥6.67

New 90-day low: CN¥7.27

New 90-day low: CN¥8.01

Third quarter earnings released

First half earnings released

New 90-day high - CN¥8.27

ShanXi C&Y Pharmaceutical Group Co., LTD. to Report First Half, 2020 Results on Aug 27, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media